[HTML][HTML] Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment
Gliflozins are a novel class of oral anti-diabetic drugs, acting as inhibitors of sodium-glucose
co-transporters (SGLTs) through the proximal convoluted tubules (PCT) and intestinal …
co-transporters (SGLTs) through the proximal convoluted tubules (PCT) and intestinal …
Pharmacological modulation of Nrf2/HO-1 signaling pathway as a therapeutic target of Parkinson's disease
Y Wang, L Gao, J Chen, Q Li, L Huo, Y Wang… - Frontiers in …, 2021 - frontiersin.org
Parkinson's disease (PD) is a complex neurodegenerative disorder featuring both motor and
nonmotor symptoms associated with a progressive loss of dopaminergic neurons in the …
nonmotor symptoms associated with a progressive loss of dopaminergic neurons in the …
Glycogen synthase kinase-3 inhibitors: preclinical and clinical focus on CNS-A decade onward
SM Arciniegas Ruiz, H Eldar-Finkelman - Frontiers in molecular …, 2022 - frontiersin.org
The protein kinase, GSK-3, participates in diverse biological processes and is now
recognized a promising drug discovery target in treating multiple pathological conditions …
recognized a promising drug discovery target in treating multiple pathological conditions …
Dapagliflozin mitigates doxorubicin-caused myocardium damage by regulating AKT-mediated oxidative stress, cardiac remodeling, and inflammation
Doxorubicin (Dox) is a commonly used anthracycline chemotherapy with a side effect of
cardiotoxicity, which may increase the risk of heart failure for cancer patients. Although …
cardiotoxicity, which may increase the risk of heart failure for cancer patients. Although …
[HTML][HTML] Cardiovascular protection by SGLT2 inhibitors–Do anti-inflammatory mechanisms play a role?
A Elrakaybi, K Laubner, Q Zhou, MJ Hug, J Seufert - Molecular metabolism, 2022 - Elsevier
Background Metabolic syndrome and related metabolic disturbances represent a state of
low-grade inflammation, which accelerates insulin resistance, type 2 diabetes (T2D) and …
low-grade inflammation, which accelerates insulin resistance, type 2 diabetes (T2D) and …
Empagliflozin alleviates endoplasmic reticulum stress and augments autophagy in rotenone-induced Parkinson's disease in rats: Targeting the GRP78/PERK/eIF2α …
Empagliflozin, a selective sodium-glucose co-transporter-2 inhibitor, has been demonstrated
to provide additional non-glycemic benefits, including neuroprotection. Endoplasmic …
to provide additional non-glycemic benefits, including neuroprotection. Endoplasmic …
Unlocking the full potential of SGLT2 inhibitors: expanding applications beyond glycemic control
The number of diabetic patients has risen dramatically in recent decades, owing mostly to
the rising incidence of type 2 diabetes mellitus (T2DM). Several oral antidiabetic …
the rising incidence of type 2 diabetes mellitus (T2DM). Several oral antidiabetic …
[HTML][HTML] The PI3K-AKT pathway: A plausible therapeutic target in Parkinson's disease
Parkinson's disease is a common progressive and multifactorial neurodegenerative disease,
characterized by the loss of midbrain dopaminergic neurons. Numerous pathological …
characterized by the loss of midbrain dopaminergic neurons. Numerous pathological …
Emergence of SGLT2 inhibitors as powerful antioxidants in human diseases
KF Tsai, YL Chen, TTY Chiou, TH Chu, LC Li, HY Ng… - Antioxidants, 2021 - mdpi.com
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of oral glucose-lowering
agents. Apart from their glucose-lowering effects, large clinical trials assessing certain …
agents. Apart from their glucose-lowering effects, large clinical trials assessing certain …
Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect?
PE Nikolaou, N Mylonas, M Makridakis… - Basic research in …, 2022 - Springer
Major clinical trials with sodium glucose co-transporter-2 inhibitors (SGLT-2i) exhibit
protective effects against heart failure events, whereas inconsistencies regarding the …
protective effects against heart failure events, whereas inconsistencies regarding the …